Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | TEK | Q02763 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705565 | 0.85 | LCK (0.65) | ABL1LCKKDRJAK3TEK | |
| SCHEMBL1704606 | 0.84 | ABL1 (0.49) | ABL1MAPK14MEN1KMT2ANPC1 | |
| SCHEMBL13220015 | 0.83 | ABL1 (0.55) | TRPV1ABL1LCKKDRJAK3 | |
| SCHEMBL1705288 | 0.82 | MAPK14 (0.57) | MAPK14HDAC6HDAC8MEN1KMT2A | |
| SCHEMBL1705324 | 0.82 | ABL1 (0.43) | ABL1MAPK14KITKMT2ANPC1 | |
| SCHEMBL1696213 | 0.81 | LDHA (0.41) | LCKMAPK14NPC1MAPTRAB9A | |
| SCHEMBL1703715 | 0.80 | DDR2 (0.54) | ABL1LCKKDRMAPK14KIT | |
| SCHEMBL1704008 | 0.79 | MAPK14 (0.44) | ABL1LCKKDRJAK3TEK | |
| SCHEMBL5497629 | 0.78 | LCK (0.71) | TRPV1LCKKDRJAK3TEK | |
| SCHEMBL1704882 | 0.77 | MAPK14 (0.68) | LCKKDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010144909-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | OAT, OTC, DLD | TRPV1 1969/4885ABL1 1023/4885LCK 1107/4885 |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | GOT2, OAT, ABAT | TRPV1 1585/4885ABL1 318/4885LCK 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.